First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabella...
CEO Christophe Weber to retire from Takeda in June 2026 after 12 years
Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process
OSAKA, Japan & ...
Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER)
Core Operating Profit Increase o...
